Published • loading... • Updated
Sanofi to pay Regeneron $1 billion upfront in expanded immunology deal
Summary by WTVB
11 Articles
11 Articles
Sanofi will pay at least $1 billion to Regeneron to develop four new antibodies. A strategic agreement to prepare the post-Dupixent, the leading drug of the French group, whose exclusivity will end in the early 2030s.
·Gennevilliers, France
Read Full Article
Health: Sanofi Signs a $1 Billion Deal with Regeneron to Produce the Successors of the Dupixent Drug
The French pharmaceutical group Sanofi again joins with the American laboratory Regeneron to develop the successors of its star medicine Sanofi will pay at least one billion
·France
Read Full Article
Sanofi to pay Regeneron $1 billion upfront in expanded immunology deal
Oct 1 (Reuters) - French drugmaker Sanofi said on Thursday it would pay US partner Regeneron $1 billion upfront and up to $7 billion more in milestone payments to add four next-generation, long-acting immunology antibodies to the partnership ...
Coverage Details
Total News Sources11
Leaning Left0Leaning Right2Center4Last UpdatedBias Distribution67% Center
Bias Distribution
- 67% of the sources are Center
67% Center
C 67%
R 33%
Factuality
To view factuality data please Upgrade to Premium
